COPILOT: Review of the Impact of a Computer-aided Real-time Polyp Detection System on Adult Colonoscopy

Sponsor
Sengkang General Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05822895
Collaborator
Medtronic (Industry)
764
1
35.9
21.3

Study Details

Study Description

Brief Summary

Background:

Removal of adenomatous polyps during colonoscopy is associated with long-term prevention of colorectal cancer-related deaths. Recently, there have been much interest in the use of artificial intelligence platforms to augment the routine endoscopic assessment of the colon to enhance adenoma detection rate (ADR). To date, computer assisted detection of polyps (CADe) have been shown to be safe, with a significant increase in ADR, without any concomitant increase in post-procedural complications.

Aims:

We aim to evaluate the use of GI GeniusTM Intelligent Endoscopy Module in a multi-ethnic Asian population (Singapore) to increase in ADR and adenoma detected per colonoscopy (ADPC)to justify its effectiveness as an adjunct in polyp detection and training for colonoscopy.

Methods:

This study will be a single-institution cohort study, conducted over a 2-year period. Sengkang General Hospital does an estimated 12,500 colonoscopies per year, with an average of 1,040 colonoscopies performed every month. Thus, given the case volume, we expect to detect differences in ADR amongst endoscopists if any during this study period.

As part of the subgroup analysis, we also aim to compare the ADR rates of trainee endoscopists with and without the GI GeniusTM Intelligent Endoscopy Module to ascertain its utility as an education tool/training adjunct

Condition or Disease Intervention/Treatment Phase
  • Device: CADe enabled programme (GI Genius)

Detailed Description

This study will be a single-institution cohort study, conducted over a 2-year period. We will recruit patients prospectively who would have their colonoscopy performed with AI guidance from the GI Genius, which is a standard of care feature in the endoscopy rooms fitted with the GI Genius, and compare it against historical data when the AI technology was not available (Jan 2018-Jan 2021). This historical data has already been collected as part of a published audit performed for SKH's endoscopy. The data collected for this historical cohort are from an anonymised database collected from OTMU (who is not involved in the study).

For the prospective cohort undergoing AI aided endoscopy (1/4/2023 - 31/3/2025):

This will include all adult patients going for colonoscopy in the our institution. Patients with incomplete or failed colonoscopy, flexible sigmoidoscopy, colonoscopy done after previous colorectal cancers or previous colonic resections, patients with poor bowel preparation, when deemed by the endoscopist to have an incomplete assessment of the colon, will be excluded from the analysis.

patient demographical data, procedural related data as well as histology from histological reports from their colonoscopy would be collected by research coordinators in order to ascertain ADR, ADPC and PDR.

These coordinators are independent of the study team and will not be part of the analysis of the data. In order to have an effective barrier (for the study team not to be able to identify the patients from the data collected), therefore the coordinators act as a trusted independent party who will extract/de-identify the data before it is handed to the study team for analysis of the ADR ADPC and PDR. The study team will not attempt to re- identify the patients back.

Analysis of data:

Subsequent analysis will be conducted at every 3 months by reviewing for the absolute ADR and ADPC amongst endoscopists by the study team. By comparing these prospectively collected data with the historical cohort data, we would be able to evaluate the effectiveness of the GI Genius in improving the ADR, PDR and ADPC. Cost analysis can also be done to analyse the cost effectiveness of the added AI feature.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
764 participants
Observational Model:
Case-Control
Time Perspective:
Other
Official Title:
A Comprehensive Review of the Impact of a COmPuter-aIded reaL-time pOlyp deTection System on Adult Colonoscopy (COPILOT Study) - a Single Institution Adoption Experience
Actual Study Start Date :
Jan 2, 2023
Anticipated Primary Completion Date :
Jun 30, 2025
Anticipated Study Completion Date :
Dec 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Computer-aided polyp detection

patients undergoing colonoscopy with CADe enabled programme

Device: CADe enabled programme (GI Genius)
CADe enabled programme (GI Genius)

without CADe

patients undergoing colonoscopy without CADe enabled programme

Outcome Measures

Primary Outcome Measures

  1. ADR [2 weeks for Histological results to return]

    Adenoma detection rate

Secondary Outcome Measures

  1. ADPC [2 weeks, for histological results to return]

    Adenoma detection per colonscopy rate

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • all adult patients going for colonoscopy in the our institution
Exclusion Criteria:
  • Patients with incomplete or failed colonoscopy, flexible sigmoidoscopy, colonoscopy done after previous colorectal cancers or previous colonic resections, patients with poor bowel preparation, when deemed by the endoscopist to have an incomplete assessment of the colon

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sengkang General Hospital Singapore Singapore 544886

Sponsors and Collaborators

  • Sengkang General Hospital
  • Medtronic

Investigators

  • Principal Investigator: Frederick H Koh, FRCSEd, Sengkang General Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sengkang General Hospital
ClinicalTrials.gov Identifier:
NCT05822895
Other Study ID Numbers:
  • 2022/2695
First Posted:
Apr 21, 2023
Last Update Posted:
Apr 21, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Keywords provided by Sengkang General Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 21, 2023